Safety Study of MGAH22 in HER2-positive Carcinomas
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Gastric Cancer
Interventions: BIOLOGICAL: margetuximab
Sponsor: MacroGenics
Collaborators: Green Cross Corporation|National Cancer Institute (NCI)